Q uadrivalent human papillomavirus (HPV) vaccine targets oncogenic HPV types 16 and 18 and nononcogenic types 6 and 11, which can cause benign cervical lesions and anogenital warts (AGW). 1 This vaccine was licensed in the United States in mid-2006 for females 2 and in late 2009 for males.
3 A 9-valent vaccine, which protects against the quadrivalent and 5 additional oncogenic HPV types, was licensed in late 2014 for males and females. 4 These vaccines are recommended for routine use in US females aged 11 to 12 years, with catch-up vaccination through age 26 years. 2, 4 Since late 2011, routine use has been recommended for males aged 11 to 12 years, with catch-up vaccination through age 21 years 5 ; vaccination through age 26 years is recommended for men who have sex with men or are immunocompromised. 4, 5 Although a bivalent vaccine was licensed for females, 6 almost all HPV vaccine administered through late 2014 was quadrivalent. 7 When HPV vaccine was first licensed in the United States, a 3-dose series of the vaccine was recommended for all recipients, with 2 doses approximately 2 months apart and a third dose 6 months after the first dose. 2, 3 In late 2016, a 2-dose series was recommended for children and adolescents who received their first dose before age 15 years; these doses should be given approximately 6 months apart. 8 HPV vaccine uptake has been low to moderate in the United States compared with some industrialized countries. 9 In girls aged 13 to 17 years, coverage with 1 or more doses increased from 25% in 2007 10 to 60% in 2014 11 ; only 40% had completed the series in 2014. 11 Vaccine uptake has been lower among boys, with 1 or more dose coverage in those aged 13 to 17 years ranging from 8% in 2011 12 to 42% in 2014. 11 In 2014, only 22% of boys had completed the series.
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HPV vaccination coverage in adults is lower than in adolescents.
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Clinical trials have demonstrated prophylactic efficacy of HPV vaccines, 16, 17 and data from high-income countries have shown population effectiveness, 18, 19 particularly in countries with high vaccination coverage. 19 Several factors complicate efforts to monitor population effectiveness, including multiple clinical sequelae, or outcomes, with variable and often extended times from infection to sequelae development. 20 Cervical cancer may take several decades to develop, 21 The significant decrease in AGW prevalence among adolescent females, the sex and age group most likely to be affected by HPV vaccination, provided early evidence of population effectiveness of HPV vaccination, despite modest levels of vaccination coverage. However, insufficient years of data were available to assess the validity of the apparent inflections (i.e., changes) in trends observed in 2009 for women aged 20 to 29 years and men aged 20 to 24 years. The potential inflection in trend among young men is particularly intriguing, because HPV vaccination coverage in this group through 2011 was extremely low 13,14 and declines in AGW prevalence would be attributable to indirect, or herd, protection from vaccination among females. 24 We sought to extend the study undertaken during 2003 to 2010 using additional years of data from the HPV vaccine postlicensure era (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) to (1) determine whether AGW prevalence continued to decline among adolescent females, (2) determine whether the apparent inflections in trend observed in 2009 among women aged 20 to 29 years and men aged 20 to 24 years were valid indicators of initial declines in AGW prevalence in these groups, and (3) examine trends in other sex and age groups to identify additional changes in AGW prevalence in the postvaccination era.
METHODS
We obtained data from approximately 100 to 170 self-insured employers and health insurance plans included in the MarketScan Commercial Claims and Encounters Database (Truven Health Analytics, Ann Arbor, MI), which represents the medical experiences of insured employees and their dependents throughout the United States. We used inpatient admissions, outpatient visits, and outpatient pharmaceutical claims from January 2006 to December 2014. We restricted claims to those of enrollees aged 15 to 39 years who were continuously enrolled throughout a given calendar year. We aggregated claims within each year so that individuals were the unit of analysis.
Anogenital Warts Case Definition
We used a number of AGW-related indicators to construct the case definition, as previously described 23 : 
Additional Analytic Factors
We stratified analyses by sex and 5-year age group. We determined whether a female had received a gynecological examination by encounter or procedure codes indicating a routine gynecological examination, cervical cancer screening, cervical or vaginal cytopathology, or HPV nucleic acid detection testing, as described previously. 23, 26 We used residence of the insured enrollee to determine geographic region (i.e., census region) and residence in a metropolitan statistical area. We categorized insurance plans as noncapitated or capitated (i.e., fee for service).
Statistical Analysis
We expressed annual AGW prevalence as number of cases per 1000 person-years. We used log binomial modeling with SAS version 9.3 (SAS Institute, Carey, NC) to obtain confidence intervals (CIs) for AGW prevalence and assess effect measure modification. We calculated percentage change in prevalence over the entire study period as the difference between the average rates during 27 We estimated annual percentage change (APC) in prevalence using Joinpoint software version 4.2.0 (National Cancer Institute, Bethesda, MD), which fits trend data to identify the log-linear model with the fewest inflection points (joinpoints). 28 We determined APC from the log-linear slope of the trend segment between joinpoints.
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RESULTS
Almost 89 million person-years of data from 35 million individuals were included in this analysis (Table 1) AGW prevalence was higher in all age groups among females who received a gynecological examination or cervical cancer screening in a given calendar year compared with those who did not (Figure A, available as a supplement to the online version of this article at http://www.ajph.org). Trends in AGW prevalence also differed between those who were examined or screened and those who were not ( Table 2 ). Among females aged 15 to 19 years, rates in both groups decreased significantly throughout the entire period; the decline was greater among those who were examined or screened (APC = -12.9; P < .001) than among those who were not (APC = -3.0; P = .031).
In women aged 20 to 24 years, rates were stable during 2006 to 2011 for those examined or screened and during 2006 to 2009 for those not examined or screened; in both groups, significant declines were then observed through 2014. Prevalence increased during 2006 to 2009 among women aged 25 to 29 years who were examined or screened (APC = 13.9; P = .002) and then decreased through 2014 (APC = -4.7; P < .001); we observed similar, but not statistically significant, trends in women in this age group who were not examined or screened. Among women aged 30 to 34 years and 35 to 39 years who were examined or screened, prevalence increased during 2006 to 2009 and then was stable through 2014; by contrast, rates increased throughout the entire period in both age groups for women who were not examined or screened.
In males, AGW prevalence increased significantly during 2006 to 2009 for all age groups (Table 2; Figure 2 For each sex, trends in AGW prevalence by age group were statistically significantly modified by each of the factors examined: geographic region, residence or nonresidence in a metropolitan statistical area, and health plan capitation or noncapitation. However, visual comparison of sex-and age groupspecific trends in AGW prevalence for each factor showed no meaningful modification of AGW trends by these factors.
DISCUSSION
The observed declines in AGW prevalence extend previous findings for MarketScan enrollees during 2003 to 2010. 23 13 AGW prevalence increased throughout the study period for women aged 35 to 39 years, who were never vaccination eligible. Note. MSA = metropolitan statistical area; PY = person-years.
We observed significant declines in AGW prevalence during 2009 to 2014 in men aged 20 to 24 years, and borderline significant decreases occurred in those aged 15 to 19 years. To our knowledge, this is the first evidence of decreased AGW prevalence among US males in the HPV vaccination era. The decreased prevalence in men aged 20 to 24 years is unlikely to be caused by male vaccination. There are several reasons for this. Almost all men in this age group were aged 19 years or older since 2011, when HPV vaccine was first recommended for routine use in US males, 5 and vaccination coverage in adult males has been extremely low, ranging from 2% in 2011 14 to 8% in 2014. 15 The most likely sexual partners for men in this age group were females of a similar age or younger, 30, 31 and therefore AGW declines in men aged 20 to 24 years are consistent with herd protection from vaccination among females.
In men aged 25 to 29 years, AGW prevalence rates were statistically stable from 2009 to 2014 but appeared to decline somewhat during 2012 to 2014; this may indicate that herd protection from vaccination among females is starting to affect men in this age group, but more years of data are needed to validate this supposition. Very few men aged 30 to 34 years would have been eligible for vaccination during the study period; a man aged 30 years in 2014 would have been 26 years old in 2010, which was 1 year after the HPV vaccine was licensed for use in males 3 but before recommended use through age 26 years in men who have sex with men or who are immunocompromised. 5 AGW prevalence among men in this age group appears to have declined slightly from 2013 to 2014, but as with men aged 25 to 29 years, more years of data are needed to verify this possible inflection in trend. It is intriguing that the potential decrease in prevalence among men aged 30 to 34 years started somewhat later, and is smaller, than the potential decline seen among men aged 25 to 29 years; it is possible that these observations reflect the diffusion of herd protection in the male population from vaccination among females.
A number of studies in high-income countries have examined the population effectiveness of HPV vaccination on clinical Continued sequelae of HPV infection, including AGW, using ecologic comparisons of pre-and postvaccination era prevalence rates. 19 In countries with low to moderate vaccination coverage among females, such as the United States, modest reductions in AGW prevalence were observed in females aged 19 years or younger, with no indication of herd protection in males within 4 years of vaccine introduction. 19 In Australia, which has achieved 70% to 80% vaccination coverage in young females, 32 32 and it is anticipated that HPV vaccination of both males and females will result in near elimination of AGW among heterosexual Australians. 32 
Limitations and Strengths
Our study has several limitations. For the MarketScan enrollees used in our current and previous analyses, 23 Although it is possible that unmeasured confounding-such as enrollment of lowerrisk persons over time from changes in participating health care plans or less detection of AGW from changes in medical practicemay be partially responsible for our findings, annual sex and age distributions were stable over the study period. The assessment of modification of sex-and age-specific trends by health plan type and residence in a metropolitan statistical area or geographic region did not reveal meaningful differences in trends. We were able to address the possibility that declines in AGW prevalence among females may be because of decreased gynecological examinations or cervical cancer screening 37 by stratifying on this factor; because most AGW diagnoses are made by clinical examination, prevalences were higher among those examined or screened in all age groups. Although the decline in prevalence among females aged 15 to 19 years who were examined or screened was stronger than among those who were not examined or screened, prevalence declined significantly among both groups as well as among those aged 20 to 24 years. Declines in examination or screening of females would not account for our findings of decreased AGW prevalence in young males.
This study also has several strengths. Because 93% of cases had a diagnosis of condylomata acuminata, the case definition is highly specific. Diagnosis codes derived from claims may include conditions that are considered but ultimately ruled out, because claims data are used for billing purposes; however, overestimation of AGW prevalence for this reason is unlikely, as AGW is a straightforward diagnosis. Although we could not distinguish incident from recurrent infections, we counted each person meeting our case definition only once per calendar year, and it is unlikely that recurrences would differ by age group and period in ways that would result in the observed declines in prevalence. Finally, use of an ecologic design did not require continuous enrollment of individuals throughout the study period, allowing us to examine annual health care experiences of very large numbers of enrollees, resulting in very stable prevalence estimates.
Conclusions
Our observations indicate that declines in AGW prevalence among US females, which were previously limited to those aged 15 to 19 years, are now occurring through age 29 years. AGW prevalence also is decreasing in males aged 15 to 24 years, particularly among those aged 20 to 24 years; because HPV vaccination coverage in US adult males has been extremely low, this decline is most likely attributable to herd protection from vaccination among females. Rates among men aged 25 to 34 years have stabilized and may be starting to decline, indicating that future decreases in AGW prevalence may be anticipated among US adult males.
Although declines in quadrivalent vaccine HPV types since initial vaccine licensure have been demonstrated in cervicovaginal and penile swab specimens, 35, 36 many HPV infections appear to be transient and may not result in clinically significant sequelae. 1, 22, 38, 39 Therefore, continued surveillance of AGW and other clinical sequelae of HPV infection is critical for monitoring the population-level effectiveness of HPV vaccination. Health claims databases and other novel surveillance data sources offer innovative and cost-effective methods for continued monitoring of the public health impact of HPV vaccination. 
